The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
about
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor geneWNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasisIntratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cellsMolecular biology of lung cancerMolecular biology of lung cancer: clinical implicationsIntegrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumorsBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsNew molecularly targeted therapies for lung cancerErbB receptors: from oncogenes to targeted cancer therapiesThe steady progress of targeted therapies, promising advances for lung cancerReview of the current targeted therapies for non-small-cell lung cancerDevelopment of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsCIViC databaseNovel mutant-selective EGFR kinase inhibitors against EGFR T790MStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancerPharmacogenomic discovery using cell-based modelsTERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung CancerGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsAKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung CancerPersonalized characterization of diseases using sample-specific networksBIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsA chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsDetection of mutations in EGFR in circulating lung-cancer cellsConditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinaseApi6/AIM/Spα/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinomaEGFR soluble isoforms and their transcripts are expressed in meningiomas.Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancerERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cellsComparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout miceOncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationErlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
P2860
Q24300355-866F7D3A-5822-48E4-A5FD-25EFCA11980AQ24310644-4B87882A-65BB-4C7C-B0D0-904493189DD8Q24603941-2D04C824-B7D6-4F0A-8CDE-CD61E10CD8EBQ24606677-D1E70401-5A3D-4FF0-B541-2E585A84E652Q24610335-E6DEBD28-E1F3-4256-BFF8-9B79804D0A5EQ24614112-AD113C8E-238D-4772-B089-2326BC1B3E48Q24649935-8B765EBC-A561-4803-9046-A57E288EE10AQ24680988-5F05C95D-8789-4250-8F6F-8B57803D017AQ24683709-9D666557-4B6D-4521-AF3C-AB0147B7DEB4Q26746895-4311A9ED-AA4B-4D30-AB47-A3FA7B0BBA95Q27015079-3C6A7CB7-4580-4844-A288-35FD194ABF8DQ27302811-32EF708C-E339-4C1A-9242-B4FEF844ED17Q27612411-C3661884-7592-4AE6-AB15-6FC03F1F560BQ27658766-36D825E9-1585-4E66-B0FE-4C9FD0DA037DQ27680966-6806359C-C71A-4D68-89E8-B8762915DB09Q27851457-DD192F5B-7E7D-4632-B70B-D5B2D0F1D4FBQ27851461-FBD30261-3261-478B-AE28-557C80E087A7Q27851896-02BDF6C3-13DD-428E-BCB9-D9AFCE4E6F54Q28115136-8D98BEC5-E927-4F24-BC56-0356B1DBDE34Q28392982-BC34F25E-86F7-408B-B3CA-D31D8D6A6CFCQ28393844-4EC78185-3A87-4709-B1B3-8F6A62E31758Q28469345-C20243E8-F79B-4FD6-B0FA-C8B55F9A417EQ28550038-2E0AF98A-B116-45E6-923A-D597657C7DB0Q28586781-89B779EC-6167-41B5-8F13-33C536B63CD4Q28756824-E427A6B6-1EFC-44FB-8FD9-1CBE54B7ECE1Q29614275-A473965C-A65F-4CB2-9732-4A36EAF5CC23Q29615033-005F5C02-2443-42FB-A23B-6DB4898F8810Q30490786-90C1F811-1650-4E9B-8AFE-22E9784CD81AQ30503504-48A90F89-667A-4F61-9395-973F5EE5760EQ31062214-57C26D0B-2DA8-4E52-9F09-27192204908AQ33304557-DD957C60-FDA7-4AD9-A813-9EA45F47A3C5Q33306709-12BF2856-C81D-4B2D-89F9-9E4FE8B555A9Q33332189-7E0BDF1B-082C-4655-8C54-3375FCA23C72Q33571026-9963FC09-452A-4B4C-83AC-274B560DB277Q33598556-68FA1726-9347-44C8-A169-C936BC118740Q33601653-68A2BEFD-9562-4B1C-855A-0F835F965398Q33636907-ACDDB05F-4909-4969-A829-CCC4968EFEDEQ33649612-98D23B7C-0492-4D6F-AB32-2B15920B10E5Q33902463-D0C22CC9-E1BB-44E1-B572-5E1B61EE87C9Q33945734-F6071AC1-6BF4-4013-987D-162C904B5E83
P2860
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@ast
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@en
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@nl
type
label
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@ast
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@en
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@nl
prefLabel
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@ast
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@en
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@nl
P2093
P50
P3181
P1433
P1476
The impact of human EGFR kinas ...... ty to EGFR-targeted therapies.
@en
P2093
Albert Mitchell
Bruce E Johnson
Daniel Tenen
Geoffrey I Shapiro
Hongbin Ji
Kate McNamara
Liang Chen
Lucian R Chirieac
Norman E Sharpless
P304
P3181
P356
10.1016/J.CCR.2006.04.022
P577
2006-06-01T00:00:00Z